VERTEX PHARMACEUTICALS INCORPORATED Vertex Pharmaceuticals Incorporated Stock
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 394.3 USD | +0.20% |
|
-0.57% | -3.10% |
| Apr. 18 | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
| Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2024 * | 10.72B | Sales 2025 * | 11.74B | Capitalization | 102B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.86B | Net income 2025 * | 4.44B | EV / Sales 2024 * | 7.91 x |
| Net cash position 2024 * | 16.91B | Net cash position 2025 * | 21.28B | EV / Sales 2025 * | 6.85 x |
| P/E ratio 2024 * |
26.4
x | P/E ratio 2025 * |
23
x | Employees | 5,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
| 1 day | +0.20% | ||
| 1 week | -0.57% | ||
| Current month | -5.68% | ||
| 1 month | -5.04% | ||
| 3 months | -9.37% | ||
| 6 months | +8.08% | ||
| Current year | -3.10% |
1 week
391.01
402.49
1 month
391.01421.45
Current year
391.01448.40
1 year
316.43448.40
3 years
176.36448.40
5 years
164.07448.40
10 years
62.41448.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 19-04-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.67% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 393.5 | +0.10% | 949,091 |
| 24-04-17 | 393.1 | -0.27% | 881,020 |
| 24-04-16 | 394.2 | -0.80% | 695,469 |
| 24-04-15 | 397.4 | +0.20% | 1,373,702 |
| 24-04-12 | 396.6 | -0.92% | 1,200,426 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
393.5
USD
Average target price
460.3
USD
Spread / Average Target
+16.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B | |
| -23.23% | 8.57B |
- Stock Market
- Equities
- VRTX Stock
